Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

Jon B. Toledo, Hugo Vanderstichele, Michal Figurski, Paul S. Aisen, Ronald Carl Petersen, Michael W. Weiner, Clifford R Jr. Jack, William Jagust, Charles Decarli, Arthur W. Toga, Estefanía Toledo, Sharon X. Xie, Virginia M Y Lee, John Q. Trojanowski, Leslie M. Shaw

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Previous studies of Aβ plasma as a biomarker for Alzheimer's disease (AD) obtained conflicting results. We here included 715 subjects with baseline Aβ 1-40 and Aβ 1-42 plasma measurement (50% with 4 serial annual measurements): 205 cognitively normal controls (CN), 348 patients mild cognitive impairment (MCI) and 162 with AD. We assessed the factors that modified their concentrations and correlated these values with PIB PET, MRI and tau and Aβ 1-42 measures in cerebrospinal fluid (CSF). Association between Aβ and diagnosis (baseline and prospective) was assessed. A number of health conditions were associated with altered concentrations of plasma Aβ. The effect of age differed according to AD stage. Plasma Aβ 1-42 showed mild correlation with other biomarkers of Aβ pathology and were associated with infarctions in MRI. Longitudinal measurements of Aβ 1-40 and Aβ 1-42 plasma levels showed modest value as a prognostic factor for clinical progression. Our longitudinal study of complementary measures of Aβ pathology (PIB, CSF and plasma Aβ) and other biomarkers in a cohort with an extensive neuropsychological battery is significant because it shows that plasma Aβ measurements have limited value for disease classification and modest value as prognostic factors over the 3-year follow-up. However, with longer follow-up, within subject plasma Aβ measurements could be used as a simple and minimally invasive screen to identify those at increased risk for AD. Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ.

Original languageEnglish (US)
Pages (from-to)401-413
Number of pages13
JournalActa Neuropathologica
Volume122
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Biomarkers
Alzheimer Disease
Cerebrospinal Fluid
Pathology
Infarction
Longitudinal Studies
Health

Keywords

  • Alzheimer disease
  • Amyloid beta-peptides
  • Biomarker
  • Cerebrospinal fluid
  • Diagnosis
  • PET
  • Prognosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S., Petersen, R. C., Weiner, M. W., ... Shaw, L. M. (2011). Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica, 122(4), 401-413. https://doi.org/10.1007/s00401-011-0861-8

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. / Toledo, Jon B.; Vanderstichele, Hugo; Figurski, Michal; Aisen, Paul S.; Petersen, Ronald Carl; Weiner, Michael W.; Jack, Clifford R Jr.; Jagust, William; Decarli, Charles; Toga, Arthur W.; Toledo, Estefanía; Xie, Sharon X.; Lee, Virginia M Y; Trojanowski, John Q.; Shaw, Leslie M.

In: Acta Neuropathologica, Vol. 122, No. 4, 10.2011, p. 401-413.

Research output: Contribution to journalArticle

Toledo, JB, Vanderstichele, H, Figurski, M, Aisen, PS, Petersen, RC, Weiner, MW, Jack, CRJ, Jagust, W, Decarli, C, Toga, AW, Toledo, E, Xie, SX, Lee, VMY, Trojanowski, JQ & Shaw, LM 2011, 'Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI', Acta Neuropathologica, vol. 122, no. 4, pp. 401-413. https://doi.org/10.1007/s00401-011-0861-8
Toledo, Jon B. ; Vanderstichele, Hugo ; Figurski, Michal ; Aisen, Paul S. ; Petersen, Ronald Carl ; Weiner, Michael W. ; Jack, Clifford R Jr. ; Jagust, William ; Decarli, Charles ; Toga, Arthur W. ; Toledo, Estefanía ; Xie, Sharon X. ; Lee, Virginia M Y ; Trojanowski, John Q. ; Shaw, Leslie M. / Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. In: Acta Neuropathologica. 2011 ; Vol. 122, No. 4. pp. 401-413.
@article{7b60a1edf26441dc8e2c5fb028fb29ec,
title = "Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI",
abstract = "Previous studies of Aβ plasma as a biomarker for Alzheimer's disease (AD) obtained conflicting results. We here included 715 subjects with baseline Aβ 1-40 and Aβ 1-42 plasma measurement (50{\%} with 4 serial annual measurements): 205 cognitively normal controls (CN), 348 patients mild cognitive impairment (MCI) and 162 with AD. We assessed the factors that modified their concentrations and correlated these values with PIB PET, MRI and tau and Aβ 1-42 measures in cerebrospinal fluid (CSF). Association between Aβ and diagnosis (baseline and prospective) was assessed. A number of health conditions were associated with altered concentrations of plasma Aβ. The effect of age differed according to AD stage. Plasma Aβ 1-42 showed mild correlation with other biomarkers of Aβ pathology and were associated with infarctions in MRI. Longitudinal measurements of Aβ 1-40 and Aβ 1-42 plasma levels showed modest value as a prognostic factor for clinical progression. Our longitudinal study of complementary measures of Aβ pathology (PIB, CSF and plasma Aβ) and other biomarkers in a cohort with an extensive neuropsychological battery is significant because it shows that plasma Aβ measurements have limited value for disease classification and modest value as prognostic factors over the 3-year follow-up. However, with longer follow-up, within subject plasma Aβ measurements could be used as a simple and minimally invasive screen to identify those at increased risk for AD. Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ.",
keywords = "Alzheimer disease, Amyloid beta-peptides, Biomarker, Cerebrospinal fluid, Diagnosis, PET, Prognosis",
author = "Toledo, {Jon B.} and Hugo Vanderstichele and Michal Figurski and Aisen, {Paul S.} and Petersen, {Ronald Carl} and Weiner, {Michael W.} and Jack, {Clifford R Jr.} and William Jagust and Charles Decarli and Toga, {Arthur W.} and Estefan{\'i}a Toledo and Xie, {Sharon X.} and Lee, {Virginia M Y} and Trojanowski, {John Q.} and Shaw, {Leslie M.}",
year = "2011",
month = "10",
doi = "10.1007/s00401-011-0861-8",
language = "English (US)",
volume = "122",
pages = "401--413",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

AU - Toledo, Jon B.

AU - Vanderstichele, Hugo

AU - Figurski, Michal

AU - Aisen, Paul S.

AU - Petersen, Ronald Carl

AU - Weiner, Michael W.

AU - Jack, Clifford R Jr.

AU - Jagust, William

AU - Decarli, Charles

AU - Toga, Arthur W.

AU - Toledo, Estefanía

AU - Xie, Sharon X.

AU - Lee, Virginia M Y

AU - Trojanowski, John Q.

AU - Shaw, Leslie M.

PY - 2011/10

Y1 - 2011/10

N2 - Previous studies of Aβ plasma as a biomarker for Alzheimer's disease (AD) obtained conflicting results. We here included 715 subjects with baseline Aβ 1-40 and Aβ 1-42 plasma measurement (50% with 4 serial annual measurements): 205 cognitively normal controls (CN), 348 patients mild cognitive impairment (MCI) and 162 with AD. We assessed the factors that modified their concentrations and correlated these values with PIB PET, MRI and tau and Aβ 1-42 measures in cerebrospinal fluid (CSF). Association between Aβ and diagnosis (baseline and prospective) was assessed. A number of health conditions were associated with altered concentrations of plasma Aβ. The effect of age differed according to AD stage. Plasma Aβ 1-42 showed mild correlation with other biomarkers of Aβ pathology and were associated with infarctions in MRI. Longitudinal measurements of Aβ 1-40 and Aβ 1-42 plasma levels showed modest value as a prognostic factor for clinical progression. Our longitudinal study of complementary measures of Aβ pathology (PIB, CSF and plasma Aβ) and other biomarkers in a cohort with an extensive neuropsychological battery is significant because it shows that plasma Aβ measurements have limited value for disease classification and modest value as prognostic factors over the 3-year follow-up. However, with longer follow-up, within subject plasma Aβ measurements could be used as a simple and minimally invasive screen to identify those at increased risk for AD. Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ.

AB - Previous studies of Aβ plasma as a biomarker for Alzheimer's disease (AD) obtained conflicting results. We here included 715 subjects with baseline Aβ 1-40 and Aβ 1-42 plasma measurement (50% with 4 serial annual measurements): 205 cognitively normal controls (CN), 348 patients mild cognitive impairment (MCI) and 162 with AD. We assessed the factors that modified their concentrations and correlated these values with PIB PET, MRI and tau and Aβ 1-42 measures in cerebrospinal fluid (CSF). Association between Aβ and diagnosis (baseline and prospective) was assessed. A number of health conditions were associated with altered concentrations of plasma Aβ. The effect of age differed according to AD stage. Plasma Aβ 1-42 showed mild correlation with other biomarkers of Aβ pathology and were associated with infarctions in MRI. Longitudinal measurements of Aβ 1-40 and Aβ 1-42 plasma levels showed modest value as a prognostic factor for clinical progression. Our longitudinal study of complementary measures of Aβ pathology (PIB, CSF and plasma Aβ) and other biomarkers in a cohort with an extensive neuropsychological battery is significant because it shows that plasma Aβ measurements have limited value for disease classification and modest value as prognostic factors over the 3-year follow-up. However, with longer follow-up, within subject plasma Aβ measurements could be used as a simple and minimally invasive screen to identify those at increased risk for AD. Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ.

KW - Alzheimer disease

KW - Amyloid beta-peptides

KW - Biomarker

KW - Cerebrospinal fluid

KW - Diagnosis

KW - PET

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=80054705807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054705807&partnerID=8YFLogxK

U2 - 10.1007/s00401-011-0861-8

DO - 10.1007/s00401-011-0861-8

M3 - Article

C2 - 21805181

AN - SCOPUS:80054705807

VL - 122

SP - 401

EP - 413

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 4

ER -